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Introduction: In emergency department (ED) patients with upper abdominal pain, management
includes ruling out serious diseases and providing symptomatic relief. One of the major causes
of upper abdominal pain is an ulcer caused by Helicobacter pylori (H. pylori), which can be
treated and cured with antibiotics. We sought to estimate the prevalence of H. pylori infection
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in symptomatic patients using a convenience sample at a single urban academic ED and
demonstrate the feasibility of ED-based testing. Methods: We prospectively enrolled patients with
a chief complaint of pain or discomfort in the upper abdomen for 1 year from February 2011 until
February 2012 at a single academic urban ED. Enrolled subjects were tested for H. pylori using
a rapid point of care 13C Urea Breath Test (UBT) [Exalenz Bioscience]. We compared patient
characteristics between those who tested positive versus negative for the disease.Results: A total
of 205 patients with upper abdominal pain were tested over 12 months, and 24% (95% confidence
interval: 19% to 30%) tested positive for H. pylori.  Black subjects were more likely to test positive
than white subjects (28% v. 6%, P < 0.001). Other factors, such as age and sex, were not different
between the 2 groups.Conclusion: In our ED, H. pylori infection was present in 1 in 4 patients
with epigastric pain, and testing with a UBT was feasible. Further study is needed to determine
the risk factors associated with infection, the prevalence of H. pylori in other EDs, the effect of the
test on ED length of stay and the cost-effectiveness of an ED-based test-and-treat strategy. [West
J Emerg Med. 2013;14(3):278–282.]
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Introduction: In emergency department (ED) patients with upper abdominal pain, management includes 
ruling out serious diseases and providing symptomatic relief. One of the major causes of upper abdominal 
pain is an ulcer caused by Helicobacter pylori (H. pylori), which can be treated and cured with antibiotics. 
We sought to estimate the prevalence of H. pylori infection in symptomatic patients using a convenience 
sample at a single urban academic ED and demonstrate the feasibility of ED-based testing. 
Methods: We prospectively enrolled patients with a chief complaint of pain or discomfort in the upper 
abdomen for 1 year from February 2011 until February 2012 at a single academic urban ED. Enrolled 
subjects were tested for H. pylori using a rapid point of care 13C Urea Breath Test (UBT) [Exalenz 
Bioscience]. We compared patient characteristics between those who tested positive versus negative for 
the disease.
Results: A total of 205 patients with upper abdominal pain were tested over 12 months, and 24% (95% 
confidence interval: 19% to 30%) tested positive for H. pylori.  Black subjects were more likely to test 
positive than white subjects (28% v. 6%, P < 0.001). Other factors, such as age and sex, were not 
different between the 2 groups.
Conclusion: In our ED, H. pylori infection was present in 1 in 4 patients with epigastric pain, and 
testing with a UBT was feasible. Further study is needed to determine the risk factors associated with 
infection, the prevalence of H. pylori in other EDs, the effect of the test on ED length of stay and the cost-
effectiveness of an ED-based test-and-treat strategy. [West J Emerg Med. 2013;14(3):278–282.]
INTRODUCTION 
Helicobacter pylori, H. pylori, is one of the most common 
worldwide human pathogens, estimated to infect the stomachs 
of approximately 60% of the world’s adult population.1 In 
the United States (U.S.), the current overall prevalence of H. 
pylori in adults is unknown but has been trending downward 
from approximately 32% in 1994.2,3 People infected with 
George Washington University School of Medicine, Department of 
Emergency Medicine, Washington, DC
Johns Hopkins University Bloomberg School of Public Health, Baltimore, 
Maryland
*
†
H. pylori are more likely to develop duodenal and gastric 
ulcers, gastric lymphoma and gastric cancer. The eradication 
of H. pylori is associated with ulcer healing, gastrointestinal 
symptom improvement and a lower likelihood of ulcer 
recurrence and bleeding. 
Estimating prevalence is important because, in an 
outpatient setting with high prevalence (>10%), current 
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gastroenterology specialty guidelines recommend a test-and-
treat strategy for patients with uninvestigated dyspepsia who 
do not have any alarm features.4 To our knowledge, no one 
has investigated the prevalence of active H. pylori infection 
among patients who present to the emergency department 
(ED) with abdominal pain.  The purpose of this study was to 
describe the feasibility of using the point-of-care 13C Urea 
Breath Test (UBT) to identify active H. pylori infection in 
patients who presented to a single, academic ED with a chief 
complaint of upper abdominal pain. In addition, we planned 
to estimate the prevalence of H. pylori as a basis for future 
studies and prior to implementation of a test-and-treat strategy.
METHODS
Study Design
Research assistants (RA) prospectively identified a 
convenience sample of adult patients with upper abdominal 
pain that was possibly caused by gastritis, dyspepsia 
or peptic ulcer disease. Eligible patients who agreed to 
participate signed a written consent form, answered a 1-page 
questionnaire and received a 13C Urea Breath Test prior to ED 
discharge. Subjects who tested positive for H. pylori were 
prescribed a treatment regimen according to the American 
Gastroenterology Association guidelines; for those who 
tested negative, treatment was left to the discretion of the 
primary provider. This study was approved by the university’s 
institutional review board.
Study Setting
The setting was a single-center, urban, academic ED with 
an annual volume of approximately 70,000 visits. The ED 
is associated with a mid-sized (371 inpatient beds) hospital 
with a Level 1 trauma center.  The ED is staffed by board-
certified emergency physicians (EP), midlevel providers and 
emergency medicine residents completing a 4-year residency 
program.
Study Population
To be eligible for the study, RAs identified patients aged 
18 and older who presented to the study ED during a 1-year 
period beginning February 14, 2011 until February 7, 2012 
with upper abdominal pain and received confirmation from 
the treating provider that the patient’s abdominal pain could 
possibly be due to gastritis, dyspepsia or peptic ulcer disease. 
Patients were excluded from participation if they were 
pregnant, currently taking antibiotics, bismuth or proton pump 
inhibitors (PPIs), or they were unable to walk to the testing 
area.  We excluded patients taking antibiotics, bismuth and 
PPIs because these medications decrease test sensitivity. 
The RAs asked all eligible subjects to sign a written 
consent form. The RAs were trained in clinical research 
through structured seminars and supervised by a senior 
research study coordinator working in the ED. Generally, the 
RAs worked weekdays between the hours of 9AM - 5PM, but 
the coverage was not consistent throughout the study period. 
When a RA was working in the ED, they attempted to enroll 
consecutive patients. 
Study Protocol
RAs administered the 13C UBT on all enrolled subjects. 
We used the 13C-BreathID, which is a rapid UBT that has 
been approved by the Food and Drug Administration for the 
diagnosis of H. pylori. All patients had been nil per os (NPO) 
for 1 hour prior to test. To perform the test, subjects breathe 
normally through a nasal cannula attached to the BreathID 
device, a machine about the size of an EKG machine or small 
ultrasound machine (Figure). After establishing a baseline 
13CO2/
12CO2 ratio, the system prompts the RA to administer 
a 75 mg 13C-urea tablet (tablet form 99% 13C enriched urea) 
and 4.5 g citric acid-based powder (4 g citric acid, 0.149 mg 
aspartate, orange aroma, and FD&C yellow acid (Tartrazine)) 
dissolved in approximately 200 mL tap water.  On the basis of 
molecular correlation spectrometry, the BreathID continuously 
measures 13CO2 and 
12CO2 concentrations from the patient’s 
breath and establishes the 13CO2/
12CO2 ratio, which is 
displayed versus time on the screen. 
High urease activity detected on exhalation is a marker 
of H. pylori infection with a sensitivity and specificity greater 
than 95%.5 The cutoff point or threshold for the BreathID 
has been determined to be 5 [delta] over baseline. Thus, a 
test result is defined as positive if the final reading is greater 
5. Test sensitivity is decreased by medications that reduce 
organism density or urease activity; so it is recommended that 
bismuth and antibiotics be withheld for at least 28 days and 
PPIs for 7-14 days prior to the UBT. Results were obtained 
within 10 to 15 minutes and printed automatically. Training 
was provided by a manufacturer representative and consisted 
of a 30-minute demonstration to the principal investigator (PI) 
and the study coordinator. The PI and coordinator then trained 
the RAs to properly administer the test. 
Figure. Nasal cannula attached to the BreathID device.
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Both the subjects and the treating EPs were informed of 
the results after the test was completed.  Interpretation of the 
test was performed at the point of care. Assuming no allergies 
to penicillin, subjects who tested positive were prescribed 
triple-therapy (clarithromycin 500 mg po BID, amoxicillin 
1000 mg BID and omeprazole 20 mg BID for 10 days, first-
line treatment per American Gastroenterological Association 
[AGA]) and referred to outpatient gastroenterology for 
followup.4 Subjects who tested negative were treated at 
discretion of the EP. The RAs recorded the UBT results and 
basic demographic information (age, gender, race, ethnicity 
and insurance status) using structured data collection sheets. 
These data were then entered into REDCap, an X electronic 
data capture tools.6 
The primary outcome was rate of positivity for H. 
pylori among those enrolled. First, using chi-square test 
of homogeneity, we compared limited demographic and 
clinical characteristics of subjects with upper abdominal pain 
whom we enrolled in the study to all patients who presented 
to the study ED with a chief complaint of abdominal pain 
during hours when the RAs were working. Differences were 
considered statistically significant if the associated p-value ≤ 
0.05. Second, we calculated the active H. pylori infection rate 
and 95% confidence interval (CI) by age, gender and race/
ethnicity. Finally, we calculated the time to disposition from 
a query of the electronic medical record for all groups as an 
objective marker of feasibility. We conducted all analyses 
using Statistical Analysis Software (SAS) version 9.2, Cary, 
North Carolina. 
 
RESULTS
There were no significant differences between the 
abdominal pain patients we screened for the study during 
the hours when the RAs were working versus hours when 
the RAs were not working by demographics (age, gender or 
race), triage acuity or time of day or day of week (Table 1). 
The average age of those enrolled and tested for H. pylori was 
38 years. Almost two-thirds of study subjects were female 
(65 %) and the majority were black (53%). Three hundred 
seventy-onepatients were screened for eligibility, and the 
most common reasons for exclusion from the study were 
Table 2. Prevalence of H. pylori Infection in study sample by 
demographic characteristics.
Characteristic N Prevalence (95% confidence 
interval)
Overall 205 24% (18%, 30%)
Age
  18 – 34 99 22% (14%, 30%)
  35 – 54 79 23% (14%, 32%)
  ≥ 55 27 33% (15%, 51%)
Gender
  Male 74 26% (16%, 36%)
  Female 131 23% (16%, 30%)
Race*
  White 53 6% (0%, 12%)
  Black 110 28% (20%, 36%)
  Other 26 27% (10%, 44%)
* Race is missing in 16 participants. 
Table 1. Percent distribution of all emergency department visits 
with abdominal pain compared to study sample by H. pylori status. 
Characteristic All abdominal
pain
n=1,039
Study 
sample
n=205
H. pylori 
positive
n=49
H. pylori 
negative
n=156
Age
  18 – 34 46% 48% 45% 49%
  35 – 54 33% 39% 37% 39%
  ≥ 55 20% 13% 18% 12%
Female 68% 64% 61% 65%
Race*
  White 28% 28% 7% 34%
  Black 62% 58% 76% 53%
  Other 10% 14% 17% 13%
Triage acuity
  1-2 13% 10% 10% 10%
  3 79% 82% 84% 81%
  4 – 5 8% 8% 6% 9%
Arrival time
  7AM – 11AM 25% 39% 45% 37%
  11AM – 3PM 51% 44% 39% 46%
  3PM – 7PM 24% 17% 16% 17%
Day of week
  Monday 21% 23% 33% 20%
  Tuesday 21% 22% 22% 22%
  Wednesday 20% 18% 10% 20%
  Thursday 20% 22% 25% 22%
  Friday 18% 15% 10% 16%
Time to 
disposition**
< 2 hrs 22% 13% 4% 15%
2-4 hrs 23% 22% 20% 22%
4-6 hrs 35% 45% 43% 46%
> 6 hrs 20% 21% 33% 17%
* Race is missing in 16 participants. 
**Significant difference between all abdominal pain patients and 
study sample’s time to disposition, and significant difference 
between H. pylori positive and H. pylori negative patients’ time to 
disposition.
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that the patient was currently on a PPI (n = 31), the patient 
was currently taking antibiotics (n = 24), the patient declined 
the test (n = 20), or, the patient had taken bismuth or pepto-
bismol earlier that same day (n = 18.) The remaining subjects 
who were screened did not have upper abdominal pain when 
approached.
A total of 205 patients with upper abdominal pain were 
tested over 12 months, and 24% (95% CI: 19% to 30%) tested 
positive for H. pylori. H. pylori infection was significantly 
more prevalent among black subjects compared to whites 
(Table 2). Black subjects were significantly more likely to 
test positive than white subjects by chi-square test (28% v. 
6%, P < 0.001). Other factors, such as age and sex, were 
not different between the 2 groups. The time to disposition 
appeared longer in the study group versus the general pool of 
abdominal pain patients. Past medical history was recorded for 
all enrolled subjects. Twenty-three (17.3 %) subjects reported 
a history of ulcer or gastritis or reflux; 4 (3%) subjects had 
diabetes mellitus; 7 (5.3%) had gallstones; 3 (2.3%) had liver 
disease; and, 4 (3%) had pancreatitis. In addition, 15 (11.3%) 
subjects were active smokers, 12 (9%) subjects were previous 
smokers and 4 (3%) reported drinking more than 5 drinks 
per day. Twenty-two (25.6%) subjects were currently taking 
PPI antacids and 22 (25.6%) reported to take NSAIDs on 
most days. A total of 42 (48.8%) subjects described pain that 
started more than 2 days prior to the ED visit. Twelve subjects 
received an ultrasound as part of ED evaluation, 14 received 
a computered tomography as part of ED evaluation, and 29 
(19.3%) of subjects received intravenous narcotics as part of 
ED management.
DISCUSSION
This study demonstrated that approximately one-quarter 
of ED patients with upper abdominal pain had active H. pylori 
infections. Some patients infected by H. pylori may have had 
peptic ulcers or gastritis or non-ulcer dyspepsia, diseases in  
which clinical benefit has been demonstrated after eradication 
therapy. The test-and-treat strategy has been demonstrated to 
decrease morbidity and promote cost-effective care in prior 
studies in the outpatient setting with high prevalence.7  If 
prevalence is high, a similar strategy applied in the ED could 
benefit patients and the overall healthcare system.  In our 
experience, the UBT was a promising test to utilize in the ED 
because of the rapid result, the ease of test, the tolerability 
of test, and the ability to change management of a common 
complaint. There was a small but significant increase among 
the study population in the percent of patients who did not 
receive a disposition under 2 hours. Whether the test will be 
feasible in other EDs that lack resources similar to our ED is 
unknown. 
Racial and socioeconomic disparity in H. pylori infection 
rates have been described previously.8 If the racial disparities 
observed in our ED are also observed in other EDs and 
in follow-up studies designed to primarily explore this 
association, then conducting H. pylori testing in EDs that 
treat a predominance of non-white patients may be a useful 
strategy. In general, the prevalence rates that we found for 
whites and blacks are similar to the general population data.
We found the UBT to be easily administered by non-
clinical staff and well-tolerated by ED patients. The test-and-
treat strategy is recommended for outpatient settings and could 
be adopted in an ED with high local prevalence. Medicare 
reimbursement for the UBT averages $93.9 Other forms of 
testing for H. pylori infection, such as serum antibody tests, 
stool antigen test and upper endoscopy, may be less feasible 
in the ED. The serum antibody test does not distinguish if 
infection is active or resolved. The need to obtain a stool 
sample may make the stool antigen test more difficult during 
an ED visit. Finally, the upper endoscopy requires a specialist 
and procedural sedation.  
We are currently not aware of any other U.S. EDs that 
routinely perform H. pylori testing. Possible reasons why 
testing for H. pylori is not performed in the ED include the 
lack of availability of the test, the idea that dyspepsia is not 
an emergency diagnosis, or, the concern that a patient may 
not receive appropriate follow-up care.10 To address follow-
up access, we initially planned to follow all subjects for 
clinical data as outpatientsbut have not included that data 
due to incompleteness. In the future, we will follow patients 
who tested positive to determine symptom relief, H. pylori 
eradication rates and medication compliance.
There are potential clinical benefits to the test-and-treat 
strategy for ED patients with uninvestigated dyspepsia/ 
abdominal pain. First, eradication treatment with antibiotics 
can be started immediately after the initial visit in the ED.7,11 
Second, patients may be spared the cost and side effects of 
prolonged treatment with PPIs and an invasive procedure, 
such as an upper endoscopy. Third, for patients with limited 
access to primary care and specialty care, there may be an 
overall reduction in incidence of long-term H. pylori-related 
complications, such as ulcers, gastritis or neoplasm.12 Future 
studies are required to address whether patients experienced 
symptomatic improvement after therapy and whether patients 
had identifiable gastrointestinal pathology such as neoplasm, 
gastritis or ulcer. 
One potential negative result to the ED test-and–treat 
approach would be to provide false reassurance for a patient 
with pre-existing gastric cancer and to decrease likelihood that 
a patient would follow up with a GI specialist for diagnostic 
upper endoscopy. Another possible negative outcome would 
be to increase the risk of premature closure of diagnosis and 
influence a clinician to miss a different cause of the pain, such 
as pancreatitis. 
LIMITATIONS
Our study of prevalence of H. pylori infection in the ED 
has 4 limitations. First, our estimate may reflect a healthier 
sample than the general ED population of upper abdominal 
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pain because subjects were asked to walk to the UBT machine 
and not all abdominal pain patients can walk across the ED to 
take a test. Second, our study used a convenience sample that 
may introduce selection bias. We attempted to limit that source 
of bias by approaching sequential patients and by comparing 
demographics of our study sample with the general ED 
population. Third, we may have underestimated the H. pylori 
prevalence by excluding patients with active treatment for 
gastritis, including bismuth and patients taking PPIs. Fourth, 
this study occurred at a single ED, and other EDs may find a 
meaningfully different rate of H. pylori prevalence depending 
on the patient population they serve.  
CONCLUSION
We have shown approximately 25% prevalence of disease 
in symptomatic patients and demonstrated the feasibility 
of using the UBT in our ED. Based on current outpatient 
recommendations, the test-and-treat strategy to dyspepsia 
should be considered in environments that have greater than 
10% prevalence. Finally, given the apparent association with 
non-white race, this infection may represent a health disparity 
that should be addressed as part of a larger public health 
campaign. 
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